Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-89862175 · 1 trial · 1 indication
The DLTs are specific adverse events that includes high grade hematologic or non-hematologic toxicities with exceptions and/or toxicities leading to treatment discontinuation.
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product and does not necessarily have a causal relationship with the intervention. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product and does not necessarily have a causal relationship with the intervention. Severity will be graded according to the NCI-CTCAE version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.
| Arm | Type | Description |
|---|---|---|
| JNJ-89862175 | EXPERIMENTAL | Participants will receive JNJ-89862175 in Part 1 to determine the recommended phase 2 doses (RP2Ds). Dose-escalation and de-escalation will be based on study evaluation team (SET) decision. In Part 2, participants will receive JNJ-89862175 at the RP2Ds determined in Part 1. |
| Name | Type | Description |
|---|---|---|
| JNJ-89862175 | DRUG | JNJ-89862175 will be administered. |
Inclusion Criteria: * Participants must have histologically or cytologically confirmed, metastatic or unresectable solid tumor of lung adenocarcinoma, renal cell carcinoma (RCC): clear cell or papillary carcinoma, endometrioid ovarian cancer and endometrioid uterine carcinoma * Have an eastern coop...
JNJ-89862175 is an investigational small molecule being developed for the treatment of advanced-stage solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with advanced solid tumors who are aged 18 years and older.
JNJ-89862175 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker symbol JNJ. The drug is currently in Phase 1 clinical development for the treatment of advanced-stage solid tumors.
JNJ-89862175 is in Phase 1 clinical development. It is an investigational drug being studied for the treatment of advanced-stage solid tumors. The drug has not been approved by the FDA or other regulatory agencies and remains in early-stage clinical testing.
JNJ-89862175 is being studied in a Phase 1 clinical trial with the identifier NCT07223125. This trial is currently recruiting participants and aims to enroll 360 patients with advanced-stage solid tumors. The study is being conducted in the United States, France, and South Korea.
Yes, JNJ-89862175 is a small molecule drug. It is being developed as an oncology treatment for advanced-stage solid tumors. The drug is currently in Phase 1 clinical development and is being studied in an open-label, uncontrolled trial.